Canadian newcomer Liphorus sets sights on oral PCSK inhibitors
This article was originally published in Scrip
A new company, Liphorus Pharmaceuticals, has been spun out of Canada's IRCM (Institut de recherches cliniques de Montréal) to develop small-molecule drugs that inhibit PCSK9 for the treatment of high cholesterol.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.